AstraZeneca Completes Early Imaging Study in Crohn’s Disease, Nudging Pipeline Hopes for AZN
AstraZeneca ($~AZN) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca has completed a small Phase I positron emission tomography study in Crohn’s disease, titled “A Phase Ib Open Label Positron Emission Tomography Study to Assess Changes in Intestinal [11C]AZ14132516 Uptake Following Administration of Multiple Doses of AZD7798 to Patients With Crohn’s Disease.” The main goal was to see how a new drug changes intestinal inflammation signals, which may guide later stage trials and pipeline value.
The trial tested AZD7798, an oral drug candidate designed to help control gut inflammation in Crohn’s disease. It also used a tracer called [11C]AZ14132516 during scans to track how the drug affects activity in the intestines over time.
The study followed an interventional, sequential design where all patients received active treatment without randomization or a placebo group. It was open label, meaning both doctors and patients knew they were getting AZD7798, and the main purpose was to test how the body responds to the drug rather than to prove final clinical benefit.
The study was first submitted on 22 May 2024, marking the start of public disclosure and early investor visibility. The record was last updated on 13 Apr 2026, signaling that the trial is now listed as completed and that new internal data are likely available for AstraZeneca’s decision making.
For investors, completion of this early imaging study is a modest but positive signal for AstraZeneca’s immunology pipeline and long term growth story in inflammatory bowel disease. While Phase I data alone rarely move AZN shares sharply, a clean readout could support future Phase II trials, shape competitive positioning versus biologics and small molecules from peers, and gradually improve sentiment around the company’s future specialty medicine revenues.
The study is now completed and recently updated, with further details and any future results releases available on the ClinicalTrials portal.
To learn more about ~AZN’s potential, visit the AstraZeneca drug pipeline page.
